Eight Essential Medicines Are Now Manufactured Locally in the UAE
The therapies are used in hospitals and clinics across the UAE and are now manufactured at Mubadala Bio facilities, alongside a wider portfolio of six pharmaceutical assets operating in the country.
UAE-based Mubadala Bio, the biopharmaceutical arm of Mubadala Investment Company, has rolled out eight essential medicines now manufactured locally for use across hospitals, clinics, and by patients nationwide. The newly produced therapies include rivaroxaban, an anticoagulant used to prevent blood clots; linezolid, an antibiotic for drug-resistant infections; sugammadex, used to reverse anaesthesia after surgery; fluconazole, an antifungal for serious infections; pantoprazole (injectable), which reduces stomach acid; ondansetron (injectable), used to prevent nausea and vomiting linked to cancer treatment; bupivacaine, a long-acting local anaesthetic for pain control; and sodium chloride inhalation solution, which helps clear airways and remove mucus.
The products are being produced at Mubadala Bio’s UAE facilities - Gulf Inject, Wellpharma, and Bioventure Healthcare - marking a step forward in local pharmaceutical manufacturing. The company said the medicines address high-demand treatment areas and are widely used across different care settings in the country.
Mubadala Bio currently owns and operates ten pharmaceutical assets across Asia, Africa, and Europe, including six in the UAE. Its manufacturing capabilities span multiple dosage forms, from tablets and capsules to small- and large-volume injectables, as well as eye and ear drops. The company manufactures and distributes more than 10,000 products to over 100 countries worldwide.
